Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Net Cash Flow: 2019-2024

Historic Net Cash Flow for C4 Therapeutics (CCCC) over the last 6 years, with Dec 2024 value amounting to -$71.1 million.

  • C4 Therapeutics' Net Cash Flow fell 43.69% to -$19.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$840,000, marking a year-over-year increase of 36.98%. This contributed to the annual value of -$71.1 million for FY2024, which is 173.29% down from last year.
  • According to the latest figures from FY2024, C4 Therapeutics' Net Cash Flow is -$71.1 million, which was down 173.29% from $97.0 million recorded in FY2023.
  • In the past 5 years, C4 Therapeutics' Net Cash Flow registered a high of $97.0 million during FY2023, and its lowest value of -$104.9 million during FY2021.
  • Over the past 3 years, C4 Therapeutics' median Net Cash Flow value was -$46.4 million (recorded in 2022), while the average stood at -$6.8 million.
  • Its Net Cash Flow has fluctuated over the past 5 years, first tumbled by 215.05% in 2021, then surged by 309.19% in 2023.
  • Yearly analysis of 5 years shows C4 Therapeutics' Net Cash Flow stood at $91.2 million in 2020, then slumped by 215.05% to -$104.9 million in 2021, then skyrocketed by 55.80% to -$46.4 million in 2022, then spiked by 309.19% to $97.0 million in 2023, then slumped by 173.29% to -$71.1 million in 2024.